Passage Bio

Passage Bio Dividend

Dividend of Passage Bio (PASG) as of Nov 16, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Passage Bio 2026 pay?

According to the latest status from November 2026, Passage Bio paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Passage Bio price of 4.25 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Passage Bio Dividends

Historical Passage Bio Dividends
PaydateDividend

The Passage Bio Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
Jan 1, 2030 (e)
0.00 USD
The Passage Bio Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the Passage Bio Dividend Safe?

Passage Bio has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Passage Bio's Dividend Distributions

Passage Bio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Passage Bio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Passage Bio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Passage Bio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Passage Bio Stock analysis

What does Passage Bio do? Passage Bio, Inc. develops genetic medicines for rare monogenic central nervous system diseases. The company focuses on six AAV-delivered therapeutics, including PBGM01 for gangliosidosis (GM1), PBFT02 for frontotemporal dementia (FTD), and PBKR03 for Krabbe disease. PBGM01 uses an AAVhu68 capsid to deliver a functional GLB1 gene encoding beta-galactosidase, PBFT02 uses AAV1 to deliver a GRN gene encoding progranulin, and PBKR03 employs AAVhu68 to deliver a GALC gene. The firm's products target specific genetic deficiencies in the central nervous system and peripheral tissues. Passage Bio's revenue model is based on developing and advancing its therapeutic pipeline. The company generates income through partnerships and potential future sales of its AAV-based therapies once approved. The primary buyers of its products are pharmaceutical companies seeking to license or co-develop these therapies. The target segments include patients with rare genetic disorders such as GM1, FTD, and Krabbe disease, who require specialized treatments due to the monogenic nature of their conditions. The firm's pipeline consists of six therapeutics, with PBGM01, PBFT02, and PBKR03 being the most advanced. These therapies are designed to address unmet medical needs in rare CNS diseases. Passage Bio's strategy involves leveraging its AAV delivery technology to create targeted treatments that can be commercialized through partnerships with larger pharmaceutical firms. Passage Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Passage Bio stock

Passage Bio paid dividends every year for the past 0 years.

Passage Bio is assigned to the 'Health' sector.

The dividends of Passage Bio are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Passage Bio